The University of North Carolina at Chapel Hill, Department of Neurology, Division of Multiple Sclerosis is continuously recruiting study subjects for on-going clinical trials in the field of multiple sclerosis. General inclusion criteria for our study subjects are:
- Ages 18- 55 years old;
- A diagnosis of relapsing remitting multiple sclerosis with at least one flare within the past six months while on therapy;
- Not currently participating in any other clinical trial;
- No known allergy or intolerance to interferon beta, corticosteroids or any immunoglobulin product.
We are currently recruiting for the following clinical trials:
- A study to characterize the mechanism of action of interferon beta-1a therapy for RRMS.
- A trial to determine the safety and effectiveness of azathioprine (Imuran) alone or in combination with IV immunoglobulin in treatment of patients with neuromyelitis optica.
- A clinical trial to evaluate the early effects of interferon beta-1a (Rebif) and atorvastatin (Lipitor) combination therapy on clinical isolated syndrome suggestive of MS.
- A laboratory study to determine the mechanism of action of interferon beta-1b in treatment of RRMS.
- A basic science study to determine the pathways of MS disease and therapy.
- An in-vitro trial for identification of inflammatory markers in blood and CSF in subjects with multiple sclerosis.
If you or anyone you know matches the above inclusion criteria and is willing to volunteer and enroll in a clinical trial, please contact Manisha Chopra, Clinical Trials Coordinator, at (919) 843-7857, Fax 919-966-2922.